Corgi ACHR 2x Daily ETF (ACHX)
Live price chart, market sentiment, and community perspectives for Corgi ACHR 2x Daily ETF (CBOE: ACHX).
Live price chart, market sentiment, and community perspectives for Corgi ACHR 2x Daily ETF (CBOE: ACHX).
On our trading desk, we are viewing ACHX primarily as a high-beta, short-term vehicle rather than a core portfolio holding. The fund targets 2x the daily performance of Archer Aviation (ACHR), which recently entered an all-stock agreement with Boeing to acquire Wisk Aero, SkyGrid, and Insitu. While this corporate action could fundamentally alter ACHR's profile—particularly with Insitu generating over $200 million in annual revenue—the structural dynamics of a leveraged ETF demand extreme caution. Data from July 2026 shows stagnant capital flows and overbought RSI conditions, highlighting that without steady buying volume, retail investors risk rapid value erosion due to compounding effects over multi-day holds.
Looking at the quantitative structure of the Corgi ACHR 2x Daily ETF, we note an expense ratio of 0.45%, which sits noticeably higher than broader market peers like AGG.P at 0.03%. Assets under management remain relatively thin at roughly $280.25K USD, reflecting limited institutional depth. The synthetic replication method and lack of a traditional underlying index mean the fund relies entirely on daily rebalancing to match its 2x objective. For risk managers, this reinforces the warning written directly in the prospectus: the fund is built exclusively for intraday or very short-term tactical trades, making overnight or long-term positioning mathematically hazardous.
From a technical evaluation standpoint, navigating single-stock leveraged products like ACHX requires strict adherence to stop-loss protocols and real-time monitoring of the underlying security's key support levels. ACHR has been trading roughly 21.7% above its moving averages, influenced heavily by news digestion surrounding the Boeing acquisition agreement. However, oscillators and moving averages across various timeframes show mixed neutral-to-sell biases when factoring in recent price retracements from its 52-week high of $48.57 down toward the $21-$27 range observed in mid-2026. Analysts must emphasize disciplined entry and exit triggers when modeling volatility scenarios for clients.
Explore plasma cleansing, somatic organ swaps, and BCI.